In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...
LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programsPresentations reinforce potential of degraders ...
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new nonclinical data related to plixorafenib (FORE8394; formerly PLX8394), the company's novel, investigational, small-molecule, ...
A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this ...
This article is based on a poster originally authored by Qiuyuan Yang, Kaiqiang Hu, Lei Liu, Tingting Guo, Haiyan Gu, Pengwei Pan, and Fang He. The study aimed to unravel the underlying processes that ...
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results